Clinical trial
Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer
NCT00291707 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00291707 |
|---|---|
| Title | Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer |
| Official title | A Phase I Trial of Cetuximab (C225) and Pemetrexed With Concurrent Radiation in Head and Neck Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Eli Lilly and Company Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Cetuximab, Pemetrexed, radiation therapy |
| Enrollment | 40 |
| Start date | Mar 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Feb 14, 2006 |
| Last update posted | May 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: